BidaskClub upgraded shares of Impax Laboratories (NASDAQ:IPXL) from a strong sell rating to a sell rating in a report released on Saturday.

IPXL has been the subject of a number of other research reports. Zacks Investment Research downgraded Impax Laboratories from a hold rating to a sell rating in a report on Friday, October 20th. Cantor Fitzgerald reiterated a buy rating and issued a $25.00 price objective on shares of Impax Laboratories in a report on Monday, September 25th. Cowen reiterated a hold rating and issued a $16.00 price objective on shares of Impax Laboratories in a report on Friday, November 10th. Royal Bank of Canada set a $17.00 price target on Impax Laboratories and gave the company a hold rating in a report on Tuesday, October 17th. Finally, Piper Jaffray Companies restated a hold rating and set a $17.00 price target on shares of Impax Laboratories in a report on Sunday, September 17th. Three equities research analysts have rated the stock with a sell rating, ten have given a hold rating and five have assigned a buy rating to the stock. Impax Laboratories presently has an average rating of Hold and an average price target of $19.62.

Impax Laboratories (NASDAQ:IPXL) opened at $19.30 on Friday. The company has a quick ratio of 1.32, a current ratio of 1.81 and a debt-to-equity ratio of 1.59. The stock has a market capitalization of $1,430.00, a price-to-earnings ratio of -3.09, a price-to-earnings-growth ratio of 1.01 and a beta of 0.94. Impax Laboratories has a twelve month low of $7.75 and a twelve month high of $25.70.

Impax Laboratories (NASDAQ:IPXL) last posted its quarterly earnings data on Thursday, November 9th. The specialty pharmaceutical company reported $0.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.20 by $0.03. The business had revenue of $206.40 million during the quarter, compared to the consensus estimate of $208.38 million. Impax Laboratories had a positive return on equity of 9.06% and a negative net margin of 56.59%. The firm’s quarterly revenue was down 9.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.37 earnings per share. equities analysts forecast that Impax Laboratories will post 0.64 EPS for the current year.

Several institutional investors have recently added to or reduced their stakes in IPXL. Legal & General Group Plc boosted its position in shares of Impax Laboratories by 8.1% during the second quarter. Legal & General Group Plc now owns 142,452 shares of the specialty pharmaceutical company’s stock valued at $2,292,000 after buying an additional 10,618 shares during the last quarter. BNP Paribas Arbitrage SA boosted its position in shares of Impax Laboratories by 56.4% during the second quarter. BNP Paribas Arbitrage SA now owns 23,498 shares of the specialty pharmaceutical company’s stock valued at $378,000 after buying an additional 8,469 shares during the last quarter. Swiss National Bank boosted its position in shares of Impax Laboratories by 15.3% during the second quarter. Swiss National Bank now owns 116,900 shares of the specialty pharmaceutical company’s stock valued at $1,882,000 after buying an additional 15,500 shares during the last quarter. Teachers Advisors LLC boosted its position in shares of Impax Laboratories by 7.5% during the second quarter. Teachers Advisors LLC now owns 131,944 shares of the specialty pharmaceutical company’s stock valued at $2,124,000 after buying an additional 9,159 shares during the last quarter. Finally, TIAA CREF Investment Management LLC boosted its position in shares of Impax Laboratories by 1.0% during the second quarter. TIAA CREF Investment Management LLC now owns 238,473 shares of the specialty pharmaceutical company’s stock valued at $3,839,000 after buying an additional 2,463 shares during the last quarter. 90.48% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Impax Laboratories (IPXL) Upgraded at BidaskClub” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another site, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The legal version of this story can be viewed at https://www.watchlistnews.com/impax-laboratories-ipxl-upgraded-at-bidaskclub/1810081.html.

Impax Laboratories Company Profile

Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.

Analyst Recommendations for Impax Laboratories (NASDAQ:IPXL)

Receive News & Ratings for Impax Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.